Picibanil (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 278 | 巨大リンパ管奇形（頚部顔面病変） | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00010452 (ClinicalTrials.gov) | April 2000 | 2/2/2001 | Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations | Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial | Lymphatic Malformations | Drug: picibanil | University of Iowa | NULL | Completed | 6 Months | 18 Years | Both | 150 | Phase 2;Phase 3 | United States |
| 2 | NCT03427619 (ClinicalTrials.gov) | January 1, 1998 | 10/1/2018 | OK432 (Picibanil) in the Treatment of Lymphatic Malformations | OK432 (Picibanil) in the Treatment of Lymphatic Malformations | Lymphatic Malformations | Drug: OK432 | Richard JH Smith | NULL | Completed | 6 Months | 17 Years | All | 701 | Phase 4 | United States |